Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some high-level statements (e.g., myopathy/rhabdomyolysis, liver function testing schedule, contraindication in pregnancy, postmarketing memory impairment) are supported by the provided label excerpts. However, multiple claims are either not supported (e.g., generic approval year, patent/patent-expiry availability, cognitive impairment rarity and reversibility, pancreatitis severity and liver failure specifics) or are only partially supported/overstated (e.g., indication for 'heart disease' and 'risk of developing high cholesterol or heart disease' not directly stated as such; diabetes risk/monitoring not present in excerpts).
Category Scores
Accurate Statements
Lipitor can cause muscle pain, tenderness, or weakness, and patients should be advised to report unexplained muscle pain, tenderness, or weakness promptly.
Label 5.1 Skeletal Muscle: advises reporting unexplained muscle pain, tenderness, or weakness; also notes myopathy can occur and therapy should be withheld/discontinued in acute serious myopathy conditions.
Lipitor can cause rhabdomyolysis (rare cases have been reported).
Label 5.1 Skeletal Muscle: 'Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria...' and Label 6.2 Postmarketing includes rhabdomyolysis.
Regular liver function tests are recommended prior to and at 12 weeks following initiation and any elevation of dose, and periodically thereafter (e.g., semiannually).
Label 5.2 Liver Dysfunction: 'recommended that liver function tests be performed prior to and at 12 weeks following both the initiation... and any elevation of dose, and periodically (e.g., semiannually) thereafter.'
Lipitor is contraindicated in women who are pregnant or may become pregnant, due to potential fetal harm.
Label 4 Contraindications and Label 8.1 Pregnancy: 'Women who are pregnant or may become pregnant. LIPITOR may cause fetal harm...' and 'LIPTOR is contraindicated...'.
Postmarketing adverse reactions include memory impairment.
Label 6.2 Postmarketing Experience: includes 'memory impairment'.
Unsupported Statements
Atorvastatin (Lipitor) is prescribed for high cholesterol.
The provided label excerpts support hyperlipidemia indications (adjunct to diet to reduce lipid levels and treat certain dyslipidemias), but the claim is phrased generically ('high cholesterol') and is not directly quoted in the supplied indication text exactly as stated.
Atorvastatin (Lipitor) is prescribed for patients at risk of developing high cholesterol or heart disease.
The provided label excerpts describe specific adult patient populations at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia and multiple risk factors for CHD, but do not state 'risk of developing high cholesterol or heart disease' in that wording.
A generic version of Lipitor (atorvastatin) was approved by the FDA in 2011.
No approval year statement appears in the provided label excerpts.
Generic versions of Lipitor have become widely available since the patent expired in 2011.
No patent expiry or availability timeline appears in the provided label excerpts.
The muscle pain and weakness caused by Lipitor is often temporary and resolves on its own.
The label excerpt advises reporting symptoms and temporarily withholding or discontinuing in acute serious myopathy, but does not state symptoms are often temporary or resolve on their own.
Lipitor can cause liver damage particularly in patients with pre-existing liver disease.
The provided excerpt includes liver function test recommendations and dose reduction/withdrawal guidance when transaminases persist, but does not state a specific 'pre-existing liver disease' relationship for liver damage.
Lipitor has been linked to an increased risk of developing type 2 diabetes.
No diabetes risk statement is present in the provided label excerpts.
Patients with a history of diabetes or those at risk of developing type 2 diabetes should be closely monitored while taking Lipitor.
No diabetes monitoring recommendation appears in the provided label excerpts.
Some patients taking Lipitor have reported cognitive impairment, including memory loss and confusion.
The provided label excerpt includes 'memory impairment' but does not mention 'confusion' specifically.
Cognitive impairment associated with Lipitor is rare.
The provided label excerpts do not characterize cognitive impairment as rare.
Cognitive impairment associated with Lipitor typically resolves once the medication is discontinued.
No statement about resolution after discontinuation for cognitive impairment appears in the provided label excerpts.
Rhabdomyolysis is characterized by muscle breakdown and kidney damage.
The provided label excerpt states rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported, but does not define it as 'muscle breakdown and kidney damage.'
Lipitor can cause pancreatitis.
Pancreatitis is not listed among the provided adverse reactions excerpts.
Pancreatitis associated with Lipitor can be severe and potentially life-threatening.
No pancreatitis adverse reaction is present in the provided label excerpts, and no severity/life-threatening language for pancreatitis appears.
In rare cases, Lipitor can cause liver failure.
While 'hepatic failure' is listed in postmarketing experience, the provided excerpts do not state 'rare cases' or the phrasing 'liver failure.'
Lipitor-associated liver failure occurs particularly in patients with pre-existing liver disease.
The provided excerpts do not state this specific patient-population association.
Regular monitoring with liver function tests and blood work can help identify potential side effects early in patients taking Lipitor.
The label excerpts specifically recommend liver function tests prior to and at 12 weeks and periodically thereafter; they do not mention 'blood work' broadly or 'identify potential side effects early' wording.
A healthcare provider may adjust Lipitor dosage to minimize the risk of side effects.
The label excerpt supports dose reduction or withdrawal in response to persistent ALT/AST elevations, but does not state a general claim that dosage adjustment is used to minimize side effect risk.
In some cases, a healthcare provider may recommend combination therapy with other medications to reduce the risk of side effects when using Lipitor.
The provided label excerpts do not discuss combination therapy to reduce the risk of side effects.
Patients with a history of liver disease should be closely monitored while taking Lipitor.
The label excerpt includes recommendations for liver function tests prior to and after initiation/titration and periodically, but does not specifically state 'history of liver disease' as a trigger for close monitoring.
Contradictions
Low
AI Statement
The muscle pain and weakness caused by Lipitor is often temporary and resolves on its own.
Label Reference
Label 5.1 Skeletal Muscle: advises withholding or discontinuing in any patient with an acute, serious condition suggestive of myopathy; does not support that symptoms are 'often temporary and resolves on its own.'
Important Omissions
If discussing monitoring for liver dysfunction, the label specifically states timing (prior to initiation, at 12 weeks after initiation and after dose elevation, and periodically thereafter) and thresholds for action (>3× ULN on 2+ occasions; reduce dose or withdraw if persistent).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by the provided label excerpts (e.g., diabetes risk, pancreatitis, liver failure associations with pre-existing liver disease, cognitive impairment being rare and resolving after discontinuation). Unsupported/overstated safety narratives could mislead readers about risks and monitoring; however, key supported warnings (myopathy/rhabdomyolysis, liver function test schedule, contraindication in pregnancy, and postmarketing memory impairment) reduce the overall gap.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple safety and population-specific claims are not present in the provided label excerpts (notably diabetes risk, pancreatitis, cognitive impairment rarity/resolution, and generic approval/patent timeline).
Suggested Improvement
Restrict statements to the provided label-supported language: use the label's specific indications for CHD risk reduction and hyperlipidemia, follow the label's exact liver function test schedule/thresholds, and avoid unsupported claims about diabetes risk, pancreatitis, rarity, resolution after discontinuation, and patent/availability timelines.